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SETBP1 mutations as a biomarker for
myelodysplasia /myeloproliferative
neoplasm overlap syndrome
Katherine Linder, Chaitanya Iragavarapu and Delong Liu*
Abstract
Myelodysplasia (MDS) /myeloproliferative neoplasm (MPN) overlap syndrome has been described since the 2001 WHO
classification as disorders that have both proliferative and dysplastic changes simultaneously. Specific disorders include
chronic myelomonocytic leukemia (CMML), juvenile myelomonocytic leukemia (JMML), BCR-ABL negative atypical
chronic myeloid leukemia (aCML) and unclassifiable MDS/MPN (MPN/MDS-U). Recurrent gene mutations in these
conditions have been described. Among them, SETBP1 mutations have been identified in up to 32% of aCML, 24% of
JMML, 18% of CMML and 10% of MDS/MPN-U patients. The mutation hotspot lies in the amino acid residues 858–871
in the SETBP1 protein. SETBP1 mutations in MDS/MPN overlap syndrome is associated with accelerated transformation
to leukemia and poor prognosis. In this review, we summarized the latest data on the role of SETBP1 mutations in the
overlap syndrome. SETBP1 mutations may serve as a biomarker for the diagnosis and poor prognosis of the overlap
syndrome.
Keywords: SETBP1, Myelodysplasia, Myeloproliferative syndrome
Background
Myelodysplasia (MDS) /myeloproliferative neoplasm
(MPN) overlap syndrome (MMOS) has been described as
disorders that have both proliferative and dysplastic
changes simultaneously [1–5]. Specific disorders include
chronic myelomonocytic leukemia (CMML), juvenile
myelomonocytic leukemia (JMML), BCR-ABL negative
atypical chronic myeloid leukemia (aCML) and unclassifi-
able MDS/MPN (MPN/MDS-U). The overlap category of
the disorders was first defined in the 2001 WHO classifi-
cation of myeloid neoplasms [6] with the 2016 revision
adding a fifth disorder – MDS/MPN with ringed sidero-
blasts and thrombocytosis (MDS/MPN-RS-T) [7]. Among
MMOS, MDS/MPN-U represents about 2% of patients
and usually carries a very poor prognosis with median sur-
vival of 21 months [8]. The definition of MDS/MPN-U
has been updated in the 2008 version of WHO classifica-
tions [1]. A recent retrospective study validated the
MDS-IPSS scoring system in MDS/MPN-U with low risk
patients and delineated the natural history of this elusive
malignancy [9].
There are frequent mutations in MDS, MPN, and
acute myeloid leukemia (AML) [10–17]. Mutations in
several pathways have been found to be useful bio-
markers for diagnosis and some are druggable targets
[18–22]. Ruxolitinib, enasidenib, midostaurin and several
other small molecules are targeted agents in clinical ap-
plications and /or development for myeloid neoplasms
[23–28]. However, no specific genetic mutations have
been found for the MDS/MPN overlap syndrome. This
review focused on the SETBP1 gene mutations and sum-
marized the clinical correlations of the common muta-
tions in MMOS and secondary AML (sAML).
SETBP1 mutations
SETBP1 was discovered in 2001 [29]. It is localized in
chromosome 18q21.1. The cDNA encodes a protein
with 1542 amino-acid residues. SETBP1 is a 170-kDa
nuclear protein that binds to SET protein, a protein pre-
viously noted to be associated with acute undifferenti-
ated leukemia [30].
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Through whole exome sequencing of DNA from 727
patients with various myeloid malignancies, recurrent
mutations of SETBP1 were found in 52 cases (7.2%) [31].
Among them, SETBP1 mutations have been identified in
up to 32% of aCML, 24% of JMML, 18% of CMML and
10% of MDS/MPN-U patients. Somatic mutations of
SETBP1 were associated with −7/del(7q) and poor prog-
nosis, possibly due to its gain-of-function which
promotes myeloid leukemic transformation in patients
with myelodysplastic syndromes (MDS) and CMML.
These data were consistent with those from other
reports [32–35].
SETBP1 in AML transformation
The first clear link between SETBP1 and myeloid neo-
plasia was demonstrated in a patient with transformed
AML [36]. The karyotyping studies performed at pro-
gression from MDS to AML in this patient revealed a
t(12;18)(p13;q21) translocation leading to fusion between
ETV6 & SETBP1. SETBP1 protects SET from protease
cleavage. Overexpression of SETBP1 was shown to in-
crease the level of SET protein, leading to increase in
the formation of the SETBP1-SET-PP2A complex [36].
SETBP1 overexpression has been shown to confer
growth advantage in hematopoietic progenitor cells,
therefore promoting leukemogenic transformation. In a
separate study of 386 patients with MDS, SETBP1 muta-
tion was found to enhance ASXL1 mutation- induced
differentiation block, and played a role as critical drivers
in the leukemic transformation from MDS to AML [37].
SETBP1 mutations in MMOS
SETBP1 in CMML
One study using massive parallel sequencing investigated
mutational hotspots of SETBP1 in 658 patients with
MDS, CMML and sAML [38]. Among the 195 CMML
patients included, 12 (6.2%) were positive for point mu-
tations in SETBP1, a rate higher than those in MDS
(2.2%) and sAML (1.7%). The mutation hotspot affected
amino acid residues 858–871 in the SETBP1 protein.
Those CMML patients with SETBP1 mutations had
higher baseline WBC counts. SETBP1 mutations were
more commonly associated with ASXL1 mutations and
less commonly associated with TET2 mutations. After a
median follow up of 31.1 months, SETBP1 mutated pa-
tients were noted to have worse OS [mOS: 21 months
vs. 46.4 months; HR-2.23 (95% CI 1.07-4.26, p-0.028)].
Interestingly, when different CD34 positive cell fractions
were genotyped by single-cell genome sequencing, all 4
potential driver mutations (ASXL1, SETBP1, ZRSR2 &
SRSF2) occurred early in the hematopoietic stem cell
populations. However, SETBP1 mutations were noted to
occur after other driver mutations, and the mutant
SETBP1 clone became predominant with progression to
secondary AML [38]. The prevalence of SETBP1
mutations and their prognostic role in CMML were
corroborated in other reports [39–44] (Table 1).
An independent prognostic scoring system for CMML,
CPSS-Mol, was developed by incorporating clinical fea-
tures and status of 38 commonly mutated genes in
CMML [45]. The learning cohort consisted of 214
CMML patients, with 19 patients (8.9%) possessing
SETBP1 mutations. Consistent with previous reports,
SETBP1 mutations were associated with a higher WBC
count (p < 0.001) and worse OS (HR for univariate: 2.49,
p = 0.02; HR for multivariate: 2, p = 0.04). This scoring
system was then validated in a cohort of 260 patients
(24 patients possessed SETBP1 mutations; 9.2%). Based
on the CPSS-Mol scores, the high-risk group had an
overall survival of 17 months as opposed to mOS not
yet reached in the low risk group (p < 0.001). This new
scoring system may be useful in assisting clinical
decision making and future clinical trials.
SETBP1 in juvenile myelomonocytic leukemia
SETBP1 mutation has also been reported in 4.8-7.2% of
the patients with JMML [46, 47]. Most of the SETBP1
mutations co-existed with RAS pathway mutations with
a lower allele burden, suggesting a secondary role in
leukemogenesis [46]. Interestingly, this report also dem-
onstrated an increasing allele burden with each round of
intensive chemotherapy, suggestive of association of
SETBP1 mutation with resistance to cytotoxic chemo-
therapy. Higher mutation rate was reported in additional
studies [48, 49]. All these studies again confirmed poor
prognosis in patients with SETBP1 mutations (Table 2).
SETBP1 in atypical CML
aCML is one of the heterogeneous neoplasms in the
group of myelodysplastic/ myeloproliferative (MDS/
MPN) overlap syndrome. Unlike CML, there is no diag-
nostic hallmark identified in aCML [50, 51]. Due to the
Table 1 SETBP1 mutations in chronic myelomonocytic leukemia
Reference Number
of Patients
Mutation Prevalence Impact on
Survival
[38] 195 12 (6.2%) Yes (p-0.028)
[39] 179 8 (4.5%) Yes (p = 0.01)
[32] 294 21 (7.1%) No (p-0.798)
[31] 152 22 (14.5%) Yes (p-NR for
CMML cohort)
[33] 466 21 (5%) No (p-0.07)
[40] 145 26 (18%) No (p-NR)
[45] 214 – Learning
260 – Validation
19 (8.9%) – Learning
24 (9.2%) – Validation
Yes (p-0.04)
[43]* 1364 NR Yes (p < 0.001)
NR Not reported; * Meta-analysis
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poor understanding of the molecular pathogenesis of
this disease, diagnosis has remained elusive and the
prognosis is far worse than that of CML (median
survival of 37 months after diagnosis) [52]. SETBP1
mutations was reported in 17/70 aCML patients (24%)
using high throughput sequencing [34]. SETBP1 muta-
tion was associated with worsened survival (22 months
vs. 77 months, HR for death – 2.27, p = 0.01) and higher
WBC counts (81 × 103 vs. 38.5 × 103 /□L, p = 0.008). In a
separate study that included 60 aCML patients [32], 19/
60 (32%) patients were noted to have SETBP1 mutations.
SETBP1 appears to occur with significant frequency in
aCML with negative impact on prognosis. SETBP1
mutations may be a new biomarker for aCML diagnosis
and prognosis (Table 3).
SETBP1 in MDS/MPN-U
In a large study of 1130 patients with myeloid
neoplasms, SETBP1 mutations were found in 20/240
(9.3%) MDS/MPN-U patients [32]. SETBP1 mutated
(mSETBP1) patients had significantly higher WBC
counts and lower platelet counts and hemoglobin levels
than those patients with wide-type SETBP1. Dysplastic
morphology was more common in mSETBP1 cases as
compared with wild-type cases. This study also reported
a significant association of SETBP1 mutations with
isochromosome i(17)(q10). The similar findings were re-
ported by a separate group [53]. These two studies also
concurred that SETBP1 mutations were strongly associ-
ated with ASXL1 mutation. Therefore, SETBP1 muta-
tions can serve as a new biomarker for MDS/MPN-U
(Table 3).
Conclusion
SETBP1 mutations are relatively common in MDS/MPN
overlap syndrome. The mutation hotspot lies in the
amino acid residues 858–871 in the SETBP1 protein.
SETBP1 overexpression is associated with accelerated
transformation to leukemia and poor prognosis. SETBP1
mutations may serve as a biomarker for the diagnosis
and poor prognosis for the overlap syndrome.
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